Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patients
Georg Lodde(Essen University Hospital), Jürgen C. Becker(Düsseldorf University Hospital), Anja Gesierich(University of Michigan), Claudia Pföhler(Saarland University), A. Hauschild(University Hospital Schleswig-Holstein), Wolfgang Galetzka(Institut für Medizinische Informatik, Biometrie und Epidemiologie), Georgios Nikolakis(Medizinische Hochschule Brandenburg Theodor Fontane), Friedegund Meier(National Center for Tumor Diseases), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Markus Hecht(Klinik und Poliklinik für Strahlentherapie und Radioonkologie), Thilo Gambichler(Witten/Herdecke University), Thomas Eigentler(University Children's Hospital Tübingen), Selma Ugurel(Klinikum Bielefeld), Frank Meiß(University of Freiburg), Jessica C. Hassel(German Cancer Research Center), Andreas Stang(Boston University), Ulrike Leiter(University of Tübingen), Patrick Terheyden(University Hospital Schleswig-Holstein), Mazdak Dalkoohi(Klinikum Bielefeld), Rudolf Herbst(Helios Klinikum Erfurt)
Cited by 9
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k